BeiGene Expands Collaboration with Novartis
December 20 2021 - 6:08AM
Dow Jones News
By Sarah Coffey
BeiGene Ltd. on Monday said it expanded its collaboration with
Novartis Pharma AG to develop, manufacture and commercialize
BeiGene's investigational TIGIT inhibitor ociperlimab in North
America, Europe and Japan.
The companies also agreed to grant BeiGene rights to market,
promote and detail five approved Novartis oncology
products--Tafinlar dabrafenib, Mekinist trametinib, Votrient
pazopanib, Afinitor everolimus, and Zykadia ceritinib--across
designated regions of China.
The strategic collaboration is expected to advance clinical
development of ociperlimab in combination with tislelizumab,
including initiation and funding by Novartis of additional studies,
the companies said.
BeiGene will receive an upfront cash payment of $300 million
from Novartis, along with an additional payment of up to $700
million on exercise by Novartis of an exclusive time-based option
prior to mid-2023 or between then and late-2023.
Following option exercise, BeiGene is eligible to receive up to
$745 million on the achievement of regulatory approval milestones,
$1.15 billion upon the achievement of sales milestones, and
royalties on future sales of ociperlimab in the licensed territory,
which includes the U.S., Canada, Mexico, member countries of the
European Union, United Kingdom, Norway, Switzerland, Iceland,
Liechtenstein, Russia, and Japan.
Novartis will initiate and fund additional global clinical
trials with ociperlimab and BeiGene has agreed to expand enrollment
in two ongoing trials, the companies said. Following the option
exercise, Novartis would share development costs of global
trials.
BeiGene has agreed to provide 50% of the co-detailing and
co-field medical efforts in the U.S., and has an option to
co-detail up to 25% in Canada and Mexico, funded in part by
Novartis. Each party retains the worldwide right to commercialize
its propriety products in combination with ociperlimab, as is the
case with tislelizumab under the parties' existing agreement.
Ociperlimab is an investigational potent TIGIT inhibitor with
intact Fc function, believed to be critical for the anti-tumor
activities of TIGIT antibodies. An immune checkpoint molecule,
ociperlimab is currently being investigated in two global Phase 3
clinical trials, the AdvanTIG-301 and AdvanTIG-302 trials, in
combination with tislelizumab in NSCLC.
Write to Sarah Coffey at sarah.coffey@wsj.com
(END) Dow Jones Newswires
December 20, 2021 06:53 ET (11:53 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024